EndoVascular Consultants — Wilmington, Delaware

EndoVascular Consultants is a clinical research site located in Wilmington, Delaware, United States 19805.

Crixeo Clinical Trials Trust Score: 13/100 (FAILING). This profile has not yet been claimed by the site owner.

EndoVascular Consultants has participated in 3 clinical trials with 3 currently active.

Therapeutic areas: Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization.

Sponsors: Aveera Medical, Inc., Summa Therapeutics, LLC, Versono Medical Ltd.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Wilmington

Browse all research sites in Delaware · View every site in Wilmington

Sponsor Feasibility Report

Trust Score: 13/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for EndoVascular Consultants?

EndoVascular Consultants has a Crixeo Trust Score of 13/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has EndoVascular Consultants conducted?

EndoVascular Consultants has 3 clinical trials on record, with 3 currently active. Their work covers Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization.

Is EndoVascular Consultants accredited by Crixeo Clinical Trials?

EndoVascular Consultants has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about EndoVascular Consultants?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.